Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients

Journal of the National Cancer Institute

Volumn 106, Issue 2, 2014, Pages

  Passerini, Carlo Gambacorti ^a,b   Farina, Francesca ^a   Stasia, Alessandra ^a   Redaelli, Sara ^a   Ceccon, Monica ^a   Mologni, Luca ^a   Messa, Cristina ^a,b   Guerra, Luca ^b   Giudici, Giovanni ^a   Sala, Elena ^b   Mussolin, Lara ^c   Deeren, Dries ^d   King, Michael H ^e   Steurer, Michael ^f   Ordemann, Rainer ^g   Cohen, Amos M ^h   Grube, Matthias ⁱ   Bernard, Lea ^j   Chiriano, Gianpaolo ^k   Antolini, Laura ^a   Piazza, Rocco ^a   more..

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d Heilig Hart Ziekenhuis   (Belgium)

^e Trillium Health Centre Missassauga   (Canada)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^h TEL AVIV UNIVERSITY   (Israel)

ⁱ UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^j UNIVERSITÉ DE MONTRÉAL   (Canada)

^k UNIVERSITY OF GENEVA   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ASPARAGINASE; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CARMUSTINE; CISPLATIN; CRIZOTINIB; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; MELPHALAN; MEPREDNISONE; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE COURSE; DRUG MEGADOSE; ERECTILE DYSFUNCTION; EYE DISEASE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LIVER FUNCTION TEST; LYMPHOMA; MALE; MIDDLE AGED; MONOTHERAPY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT HISTORY OF CHEMOTHERAPY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RASH; THROMBOCYTOSIS; TREATMENT RESPONSE; YOUNG ADULT;

EID: 84897109567     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt378     Document Type: Article

References (22)

1. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8(1):11-23.
2. Lamant L, Meggetto F, Al Saati T, et al. High incidence of the t (2;5) (p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptasepolymerase chain reaction, and P-80 immunostaining. Blood. 1996;87(1):284-291.
3. Mason DY, Bastard C, Rimokh R, et al. CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35. Br J Haematol. 1990;74(2):161-168.
4. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994;263(5151):1281-1284.
5. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC; 2008.
6. Ferreri AJ, Govi S, Pileri SA, Savage KJ. Anaplastic large cell lymphoma, ALKpositive. Crit Rev Oncol Hematol. 2012;83(2):293-302.
7. Stein H, Foss HD, Durkop H, et al. CD30 (+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96(12):3681-3695.
8. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK-anaplastic largecell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496-5504.
9. Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31(16):1970-1976.
10. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693-1703.
11. Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med. 2011;364(8):775-776.
12. Shin HJ, Thorson P, Gu J, Katz RL. Detection of a subset of CD30+ anaplastic large cell lymphoma by interphase fluorescence in situ hybridization. Diagn Cytopathol. 2003;29(2):61-66.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-216.
14. Marubini E, Valsecchi MG. Analyzing Survival Data from Clinical Trials and Observational Studies. New York: Wiley; 1995.
15. Mussolin L, Damm-Welk C, Pillon M, et al. Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis. Leukemia. 2012;27(2):416-422.
16. Piazza R, Valletta S, Winkelmann N, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 2013;45(1):18-24.
17. Ceccon M, Mologni L, Bisson W, Scapozza L, Gambacorti-Passerini C. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. Mol Cancer Res. 2012;11(2):122-132.
18. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009;27(3):469-471.
19. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-2196.
20. Pro B, Advani RH, Brice P, et al. Long-term remissions observed in an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. ASH Ann Mtng Abst. 2012;120(21):2745.
21. Mosse YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2012;14(6):472-480.
22. Carlo Gambacorti-Passerini, C, Keizo Horibe K, Braiteh F, et al. Safety and clinical activity of crizotinib in patients with ALK-rearranged hematologic malignancies. ASH Ann Mtng Abst. 2013;122(21):4342.